Corinne Epperly
Director/Board Member at IN8BIO, INC.
Net worth: 85 246 $ as of 2024-04-29
Corinne Epperly active positions
Companies | Position | Start | End |
---|---|---|---|
IN8BIO, INC. | Director/Board Member | 2023-12-06 | - |
Career history of Corinne Epperly
Former positions of Corinne Epperly
Companies | Position | Start | End |
---|---|---|---|
CARGO THERAPEUTICS, INC. | Chief Operating Officer | 2021-04-30 | 2023-11-30 |
AVEO PHARMACEUTICALS, INC. | Director/Board Member | 2021-01-05 | 2023-01-18 |
Independent Dir/Board Member | 2021-01-05 | 2023-01-18 | |
IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 2018-12-31 | 2019-12-31 |
NOTABLE LABS, LTD. | Chief Operating Officer | 2016-12-31 | 2017-12-31 |
Goldman Sachs International
Goldman Sachs International Financial ConglomeratesFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Analyst-Equity | 2010-04-13 | 2010-09-30 |
Training of Corinne Epperly
The University of North Carolina at Charlotte | Doctorate Degree |
University of Virginia | Undergraduate Degree |
Statistics
International
United States | 7 |
Israel | 2 |
United Kingdom | 2 |
Operational
Director/Board Member | 2 |
Chief Operating Officer | 2 |
Independent Dir/Board Member | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
CARGO THERAPEUTICS, INC. | Health Technology |
IN8BIO, INC. | Health Technology |
Private companies | 3 |
---|---|
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Goldman Sachs International
Goldman Sachs International Financial ConglomeratesFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Finance |
- Stock Market
- Insiders
- Corinne Epperly
- Experience